Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 2 clinical study titled ‘A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D).’ The study aims to assess the therapeutic effect, pharmacokinetics, and safety of eluxadoline in treating IBS-D in children aged 6-17 years. This research is significant as it explores a potential treatment for a challenging condition in a young population.
The study tests eluxadoline, an oral medication administered twice daily, at doses of 25mg, 50mg, and 100mg, alongside a placebo. Eluxadoline is intended to alleviate symptoms of IBS-D by modulating gut activity.
This interventional study is randomized with a parallel assignment and triple masking, meaning participants, care providers, and investigators are unaware of the treatment allocations. The primary purpose is treatment-focused.
The study began on November 15, 2017, with the primary completion date yet to be announced. The most recent update was submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
The ongoing study could influence AbbVie’s stock performance positively by expanding its product pipeline, especially if results are favorable. This could enhance investor sentiment, particularly as the company seeks to address unmet needs in pediatric IBS-D treatment. Competitors in the gastrointestinal treatment space may also be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.